Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06203106 · ClinicalTrials.gov registry record
NYSCF Scientific Discovery Biobank
A clinical trial of Alzheimer Disease and Dementia, sponsored by New York Stem Cell Foundation Research Institute.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 1
- Study location
NCT06203106 is a study of Alzheimer Disease and Dementia that is actively recruiting participants, run by New York Stem Cell Foundation Research Institute. The registered enrollment target is 10,000 participants, above the 2,718-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (268% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06203106, a study of Alzheimer Disease and Dementia, is actively recruiting participants, sponsored by New York Stem Cell Foundation Research Institute.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.
Conditions Studied
Interventions
- OTHER Biological Sample Collection
Study Locations (1)
New York
- New York Stem Cell Foundation Research Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2022-11-10 |
| Est. Completion | 2045-11-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06203106
The ClinicalTrials.gov registry entry for NCT06203106 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,718-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (268% higher). The listed sponsor is New York Stem Cell Foundation Research Institute, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Biological Sample Collection is the first listed.
NCT06203106 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06203106 about?
NCT06203106 is a clinical study titled "NYSCF Scientific Discovery Biobank". The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the...
What is the current status of trial NCT06203106?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2022-11-10. Estimated completion is 2045-11-10.
What conditions does trial NCT06203106 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Amyotrophic Lateral Sclerosis, Huntington Disease, Frontotemporal Dementia.
What interventions are being tested in trial NCT06203106?
The interventions under investigation include: Biological Sample Collection (OTHER).
Who is sponsoring clinical trial NCT06203106?
This trial is sponsored by New York Stem Cell Foundation Research Institute, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06203106 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.